Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MBX

MBX Biosciences Inc

Feb 13 • 04:00PM ET

38.09

+0.09 0.24 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM IWN VXF XPH IBB SCHA VTWO IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	41.16%	Shs Outstand	44.72M	Perf Week	1.11%
Market Cap	1.71B	Forward P/E	-	EPS next Y	-2.95	Insider Trans	3.98%	Shs Float	26.42M	Perf Month	-11.40%
Enterprise Value	1.32B	PEG	-	EPS next Q	-0.63	Inst Own	67.30%	Short Float	7.44%	Perf Quarter	54.84%
Income	-80.50M	P/S	-	EPS this Y	57.10%	Inst Trans	23.50%	Short Ratio	2.58	Perf Half Y	188.34%
Sales	0.00M	P/B	4.39	EPS next Y	-18.35%	ROA	-23.59%	Short Interest	1.97M	Perf YTD	20.77%
Book/sh	8.67	P/C	4.37	EPS next 5Y	14.35%	ROE	-24.43%	52W High	44.89 -15.15%	Perf Year	323.69%
Cash/sh	8.72	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-20.75%	52W Low	4.81 692.40%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.13% 8.43%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.79%	Oper. Margin	-	ATR (14)	3.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.99	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	32.95	EPS Q/Q	-16.28%	SMA20	-0.21%	Beta	0.88	Target Price	61.10
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	11.14%	Rel Volume	0.73	Prev Close	38.00
Employees	43	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	90.79%	Avg Volume	761.56K	Price	38.09
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.95% -	Trades		Volume	553,306	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

Feb-11-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.11%
Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
09:55AM	Loading…
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
07:00AM	Loading…
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
08:00AM	Loading…
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM

Open in Screener

KRRO

Korro Bio Inc

Feb 13 • 04:00PM ET

11.17

-0.59 -5.02 %

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: IWM VTI LFSC IWN VXF VTWO IWC ITOT VHT IWV

Index	RUT	P/E	-	EPS (ttm)	-9.42	Insider Own	44.66%	Shs Outstand	9.40M	Perf Week	-11.14%
Market Cap	105.19M	Forward P/E	-	EPS next Y	-8.10	Insider Trans	0.00%	Shs Float	5.21M	Perf Month	24.11%
Enterprise Value	56.38M	PEG	-	EPS next Q	-2.07	Inst Own	73.81%	Short Float	21.79%	Perf Quarter	-64.45%
Income	-88.42M	P/S	14.27	EPS this Y	3.63%	Inst Trans	18.36%	Short Ratio	2.30	Perf Half Y	-43.81%
Sales	7.37M	P/B	1.06	EPS next Y	10.33%	ROA	-43.65%	Short Interest	1.14M	Perf YTD	39.45%
Book/sh	10.54	P/C	1.13	EPS next 5Y	5.84%	ROE	-63.46%	52W High	55.89 -80.01%	Perf Year	-61.59%
Cash/sh	9.93	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-62.91%	52W Low	5.20 114.63%	Perf 3Y	-70.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	33.82%	Volatility	8.27% 9.53%	Perf 5Y	-99.59%
Dividend TTM	-	EV/Sales	7.65	EPS Y/Y TTM	21.61%	Oper. Margin	-1282.04%	ATR (14)	1.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.71	Sales Y/Y TTM	-	Profit Margin	-1199.53%	RSI (14)	49.20	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.71	EPS Q/Q	14.80%	SMA20	-2.90%	Beta	2.98	Target Price	22.38
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	18.15%	Rel Volume	0.22	Prev Close	11.76
Employees	104	LT Debt/Eq	0.42	Earnings	Nov 12 AMC	SMA200	-41.60%	Avg Volume	493.99K	Price	11.17
IPO	Oct 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.98% 67.56%	Trades		Volume	107,755	Change	-5.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100

Show Previous Ratings

Feb-02-26 09:53AM	H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) (Insider Monkey)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
08:00AM	Loading…
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly) -79.31%
09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
10:31AM	Loading…
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
04:05PM	Loading…
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Open in Screener

SVRA

Savara Inc

Feb 13 • 04:00PM ET

5.60

-0.23 -3.95 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	49.66%	Shs Outstand	172.85M	Perf Week	5.66%
Market Cap	1.14B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.02%	Shs Float	102.42M	Perf Month	-6.67%
Enterprise Value	1.04B	PEG	-	EPS next Q	-0.12	Inst Own	39.69%	Short Float	20.47%	Perf Quarter	35.92%
Income	-115.64M	P/S	-	EPS this Y	-7.26%	Inst Trans	-0.98%	Short Ratio	8.30	Perf Half Y	86.05%
Sales	0.00M	P/B	10.26	EPS next Y	14.54%	ROA	-60.91%	Short Interest	20.96M	Perf YTD	-7.13%
Book/sh	0.55	P/C	9.16	EPS next 5Y	38.07%	ROE	-78.74%	52W High	7.01 -20.06%	Perf Year	97.88%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-93.14%	52W Low	1.89 196.30%	Perf 3Y	132.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.95% 6.23%	Perf 5Y	220.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.39%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-68.70%
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	-19.30%	SMA20	-0.85%	Beta	0.31	Target Price	10.81
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-6.35%	Rel Volume	0.57	Prev Close	5.83
Employees	59	LT Debt/Eq	0.32	Earnings	Nov 12 AMC	SMA200	43.09%	Avg Volume	2.53M	Price	5.60
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.66% -	Trades		Volume	1,435,760	Change	-3.95%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Feb-13-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
08:30AM	Loading…
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
11:29PM	Loading…
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
04:18PM	Loading…
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM

Open in Screener

ACLX

Arcellx Inc

Feb 13 • 04:00PM ET

68.50

-0.15 -0.22 %

Healthcare • Biotechnology • USA • NASD

Peers: ALLO GILD CRSP NTLA FATE EDIT BLUE SGMO PSTX VCNX

| Held by: VTI XBI IWM VB VXF TCAF VBK IBB IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	23.05%	Shs Outstand	57.78M	Perf Week	0.69%
Market Cap	3.96B	Forward P/E	-	EPS next Y	-3.37	Insider Trans	-0.55%	Shs Float	44.49M	Perf Month	-1.95%
Enterprise Value	3.55B	PEG	-	EPS next Q	-1.04	Inst Own	92.40%	Short Float	20.48%	Perf Quarter	-24.01%
Income	-217.90M	P/S	110.33	EPS this Y	-102.90%	Inst Trans	1.81%	Short Ratio	8.46	Perf Half Y	-4.68%
Sales	35.90M	P/B	8.98	EPS next Y	16.94%	ROA	-30.67%	Short Interest	9.11M	Perf YTD	5.06%
Book/sh	7.63	P/C	8.58	EPS next 5Y	2.35%	ROE	-47.18%	52W High	94.07 -27.18%	Perf Year	7.52%
Cash/sh	7.98	P/FCF	-	EPS past 3/5Y	-3.30% -31.14%	ROIC	-44.92%	52W Low	47.86 43.13%	Perf 3Y	125.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	80.99%	Volatility	4.23% 4.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	98.92	EPS Y/Y TTM	-425.41%	Oper. Margin	-675.67%	ATR (14)	3.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.99	Sales Y/Y TTM	-76.96%	Profit Margin	-607.01%	RSI (14)	50.15	Recom	1.35
Dividend Gr. 3/5Y	- -	Current Ratio	3.99	EPS Q/Q	-105.12%	SMA20	-0.32%	Beta	0.36	Target Price	111.94
Payout	-	Debt/Eq	0.12	Sales Q/Q	-80.99%	SMA50	1.23%	Rel Volume	0.64	Prev Close	68.65
Employees	163	LT Debt/Eq	0.10	Earnings	Nov 05 AMC	SMA200	-4.71%	Avg Volume	1.08M	Price	68.50
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.75% -51.96%	Trades		Volume	688,001	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$82
Jan-07-26	Resumed	UBS	Buy	$100
Dec-22-25	Initiated	Wells Fargo	Overweight	$100
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Oct-16-25	Initiated	Stifel	Buy	$129
Jun-17-25	Initiated	Citigroup	Buy	$110
Oct-08-24	Initiated	Redburn Atlantic	Buy	$109
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36

Show Previous Ratings

Feb-04-26 09:00AM	Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder (Business Wire)
Jan-30-26 12:24AM	UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect (Insider Monkey)
Jan-21-26 04:00PM	Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings (Business Wire)
09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Loading…
Dec-11-25 07:44AM	Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
Dec-06-25 02:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Nov-30-25 05:42AM	CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting (Insider Monkey)
Nov-18-25 04:00PM	Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition (Business Wire)
Nov-05-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition (Business Wire)
Oct-30-25 10:00AM	Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:00AM	Loading…
Oct-02-25 08:00AM	Gilead's Lost Decade Is Over. It's Time to Buy the Stock. (Barrons.com)
Sep-03-25 04:00PM	Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-28-25 04:56AM	Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial (Insider Monkey)
Aug-21-25 07:57AM	Gilead dives into in vivo cell therapy with $350M buyout of Interius (BioPharma Dive)
Aug-07-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
06:49AM	EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma (Clinical Trials Arena)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-21-25 04:00PM	Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 (Business Wire) +8.26%
May-20-25 07:46AM	Baron Discovery Fund Initiated a Position in Arcellx (ACLX) (Insider Monkey)
May-14-25 09:30AM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
May-12-25 08:25AM	Here's Why Arcellx (ACLX) Declined in Q1 (Insider Monkey)
May-08-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.27%
04:00PM	Arcellx Provides First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:51AM	Loading…
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
Apr-29-25 11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 08:49PM	Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-11-25 04:26PM	Arcellx (ACLX): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 04:00PM	Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors (Business Wire)
Feb-27-25 07:05PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.59%
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights (Business Wire)
Feb-26-25 04:00PM	Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-24-25 03:08PM	Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-19-25 10:20AM	Is Arcellx (ACLX) Poised to Capture Significant Market Share? (Insider Monkey)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-10-24 09:00PM	ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma (Clinical Trials Arena) +5.73%
Dec-09-24 04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
07:50AM	Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients (Benzinga)
Dec-08-24 11:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition (Business Wire)
Nov-13-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice (Zacks)
Nov-08-24 09:40AM	Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-07-24 05:15PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.65%
04:00PM	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:41AM	Arcellx price target raised to $106 from $81 at Morgan Stanley (TipRanks)
06:27AM	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Nov-05-24 09:00AM	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study (Business Wire)
07:19AM	Cancer cell therapy from Arcellx, Gilead shows promise in early data (BioPharma Dive)
Oct-31-24 10:43PM	Arcellx (ACLX) Surged in Q3. Heres Why (Insider Monkey)
Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lubner David Charles	Director	Jan 20 '26	Option Exercise	6.28	6,000	37,680	27,659	Jan 20 07:59 PM
Lubner David Charles	Director	Jan 20 '26	Sale	75.00	6,000	450,000	21,659	Jan 20 07:59 PM
DAVID LUBNER	Director	Jan 20 '26	Proposed Sale	68.94	15,000	1,034,100		Jan 20 04:27 PM
Heery Christopher	Officer	Jan 14 '26	Proposed Sale	68.51	5,882	402,997		Jan 14 07:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 14 07:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 14 '26	Sale	68.51	5,882	402,997	23,749	Jan 14 07:38 PM
Heery Christopher	Officer	Jan 13 '26	Proposed Sale	65.51	7,437	487,213		Jan 13 09:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 13 '26	Sale	65.51	7,437	487,213	29,631	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 12 09:32 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 12 '26	Sale	64.15	6,131	393,286	37,068	Jan 12 09:32 PM
Heery Christopher	Officer	Jan 12 '26	Proposed Sale	64.15	6,131	393,286		Jan 12 07:34 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 06 08:25 PM
Elghandour Rami	SEE REMARKS	Jan 06 '26	Option Exercise	0.00	55,991	0	782,467	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 03 '26	Option Exercise	0.00	53,098	0	726,476	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 02 '26	Option Exercise	0.00	55,459	0	673,378	Jan 06 08:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 06 '26	Option Exercise	0.00	20,530	0	64,832	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '26	Option Exercise	0.00	15,340	0	44,302	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 02 '26	Option Exercise	0.00	20,496	0	28,962	Jan 06 08:14 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	90.00	340	30,600	284	Nov 17 07:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 15 '25	Sale	91.04	5,364	488,315	8,466	Oct 15 07:28 PM
MICHELLE GILSON	Officer	Oct 15 '25	Proposed Sale	87.33	5,364	468,438		Oct 15 04:38 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 03 '25	Sale	86.00	4,882	419,870	14,894	Oct 06 07:21 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 06 '25	Sale	86.22	1,064	91,733	13,830	Oct 06 07:21 PM
MICHELLE GILSON	Officer	Oct 03 '25	Proposed Sale	82.24	5,946	488,999		Oct 03 04:26 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 30 '25	Sale	81.28	21,034	1,709,723	624	Sep 30 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 29 '25	Sale	80.16	73	5,852	21,658	Sep 29 07:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 26 '25	Sale	80.12	12,396	993,155	21,731	Sep 26 07:45 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 18 '25	Sale	80.01	3,343	267,468	34,427	Sep 19 07:22 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 19 '25	Sale	80.00	300	24,000	34,127	Sep 19 07:22 PM
CHRISTOPHER HEERY	Officer	Sep 18 '25	Proposed Sale	76.42	37,486	2,864,680		Sep 18 04:32 PM
Patel Kavita	Director	Jun 10 '25	Option Exercise	6.66	1,500	9,990	1,500	Jun 11 05:37 PM
Patel Kavita	Director	Jun 10 '25	Sale	67.36	1,500	101,040	0	Jun 11 05:37 PM
KAVITA K PATEL	Director	Jun 10 '25	Proposed Sale	66.86	1,500	100,290		Jun 10 04:25 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '25	Option Exercise	0.00	22,429	0	32,011	May 28 08:18 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	64.14	12,235	784,777	19,776	May 28 08:18 PM
Gilson Michelle	Officer	May 27 '25	Proposed Sale	64.14	12,235	784,776		May 27 06:50 PM
Patel Kavita	Director	May 20 '25	Option Exercise	6.66	1,500	9,990	1,500	May 20 07:58 PM
Patel Kavita	Director	May 20 '25	Sale	58.43	1,500	87,645	0	May 20 07:58 PM
Patel Kavita	Director	Apr 29 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 29 06:34 PM
Patel Kavita	Director	Apr 29 '25	Sale	64.20	1,500	96,300	0	Apr 29 06:34 PM
Yoon Derek	Director	Apr 29 '25	Proposed Sale	62.02	19,470	1,207,529		Apr 29 04:53 PM
Patel Kavita	Director	Apr 08 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 08 07:31 PM
Patel Kavita	Director	Apr 08 '25	Sale	57.50	1,500	86,250	0	Apr 08 07:31 PM
Patel Kavita	Director	Mar 18 '25	Option Exercise	6.66	1,500	9,990	1,500	Mar 18 07:01 PM
Patel Kavita	Director	Mar 18 '25	Sale	71.64	1,500	107,460	0	Mar 18 07:01 PM
Elghandour Rami	SEE REMARKS	Feb 26 '25	Sale	62.02	38,300	2,375,517	149,186	Feb 26 08:13 PM
Elghandour Rami	Officer	Feb 26 '25	Proposed Sale	62.02	38,300	2,375,517		Feb 26 08:11 PM
Patel Kavita	Director	Feb 25 '25	Option Exercise	6.66	1,500	9,990	1,500	Feb 25 07:09 PM
Patel Kavita	Director	Feb 25 '25	Sale	63.16	1,500	94,740	0	Feb 25 07:09 PM
KAVITA K PATEL	Director	Feb 25 '25	Proposed Sale	63.01	7,500	472,575		Feb 25 04:37 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	63.79	10,155	647,773	37,486	Feb 24 08:00 PM
Heery Christopher	Officer	Feb 24 '25	Proposed Sale	63.79	10,155	647,773		Feb 24 07:57 PM

MBX

MBX Biosciences Inc

KRRO

Korro Bio Inc

SVRA

Savara Inc

ACLX

Arcellx Inc

Upgrade your FINVIZ experience